30
Participants
Start Date
May 31, 2005
Primary Completion Date
November 30, 2012
Study Completion Date
May 31, 2015
Bortezomib
Administered by IV at 1.3 mg/m2 days 1 and 4 of each 21 day cycle.
Rituximab
Administered by IV 375 mg/m2 IV day 1 of each cycle during induction chemotherapy, then weekly for four weeks during consolidation therapy; and then once every 12 weeks for up to 5 years (or until disease progression).
Cyclophosphamide
Administered by IV at 300 mg/m2, 6 doses spaced 12 hours apart on days 1-3 of each cycle, to start after completion of rituximab infusion
Doxorubicin
Given as a continuous infusion, 50 mg/m2 over 48 hours days 1-2 of each cycle, to start after completion of rituximab infusion.
Vincristine
1 mg administered by IV on day 3 of each cycle.
Dexamethasone
40 mg orally on days 1-4 of each cycle.
University Of Wisconsin Cancer Center, Madison
University of Wisconsin, Madison
OTHER